Study evaluates novel genetic test in predicting Alzheimer's | Report finds ambiguous guidelines for cancer survivor care | Study links higher CRC risk to sulfidogenic bacteria
March 24, 2017
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
Top Story
Study evaluates novel genetic test in predicting Alzheimer's
Researchers using a new polygenic hazard score test based on genetic data from more than 70,000 elderly people with and without Alzheimer's disease found that those who scored in the top 10% for risk had a more than three times higher chance of developing Alzheimer's disease and were more likely to develop the disease at an earlier age, compared with those in the lowest 10%. The findings in PLOS Medicine suggest the test may be used in identifying healthy older patients with the greatest risk of Alzheimer's disease, said researcher Dr. Rahul Desikan.
The Guardian (London) (3/22),  The Independent (London) (tiered subscription model) (3/21) 
LinkedIn Twitter Facebook Google+ Email
Clinical News & Research
Report finds ambiguous guidelines for cancer survivor care
There were ambiguous recommendations in 83% of North American and European guidelines targeted at caring for survivors of nine common cancers, researchers found. The study in JAMA Internal Medicine showed 90% of guidelines called for physical examinations and medical history, 83% recommended imaging, 63% called for endoscopic procedures and 56% included tests for disease biomarkers.
Reuters (3/20) 
LinkedIn Twitter Facebook Google+ Email
Study links higher CRC risk to sulfidogenic bacteria
A study in the journal Gut found black patients had higher levels of sulfidogenic bacteria in colonic mucosa than white patients, which could be associated with their higher risk of colorectal cancer. Researchers said black patients also had higher intake levels of fat and animal protein, which also correlated with higher levels of sulfidogenic bacteria.
Healio (free registration)/Gastroenterology (3/20) 
LinkedIn Twitter Facebook Google+ Email
Hemodialysis may raise risks in ESRD patients with cancer
End-stage renal disease patients may have a higher risk of death if they receive hemodialysis after radiofrequency ablation for liver cancer, compared with patients who were not dialyzed, a study in the Journal of Gastroenterology and Hepatology found. The risk of death was lower for patients ages 70 and younger than in older patients, researchers said.
Physician's Briefing/HealthDay News (3/20) 
LinkedIn Twitter Facebook Google+ Email
Industry Report
Report projects growth for SPECT market
A Technavio report predicts the worldwide market for SPECT imaging will be worth $1.5 billion by 2021 with a 5% compound annual growth rate. Cardiology comprised 35% of the market last year, while oncology represented 31% of the market, according to the report. (3/23) 
LinkedIn Twitter Facebook Google+ Email
Parkinson's disease drug from Newron wins FDA nod
The FDA has approved Newron Pharmaceuticals' Xadago, or safinamide, as an add-on drug for patients with Parkinson's disease. Xadago is indicated for patients who already take levodopa/carbidopa but experience "off" episodes in which the treatment is not effective.
Reuters (3/21),  Pharmacy Times online (3/21) 
LinkedIn Twitter Facebook Google+ Email
News from the Field
Mass. close to reaching 80% CRC screening goal
Massachusetts is just 4 percentage points away from reaching a nationwide goal of having 80% of adults ages 50 and older screened for colorectal cancer by 2018. Neil Maniar of the American Cancer Society said the remaining 4% represent population-based disparities and people who feel good and do not get tested, and he adds that increased public awareness and working with community groups on screening strategies can help. (New Bedford, Mass.) (tiered subscription model) (3/21) 
LinkedIn Twitter Facebook Google+ Email
Health Policy
FDA's orphan drug program to be investigated by GAO
The Government Accountability Office confirmed it will investigate the FDA's orphan drug program for potential abuses after three US senators requested the probe. The investigation, which is expected to begin in nine months, will include a request for a listing of drugs approved or denied orphan status by the FDA, an evaluation of whether reviews are consistent and an analysis of the FDA's ability to keep up with orphan drug applications.
Kaiser Health News (3/21) 
LinkedIn Twitter Facebook Google+ Email
Advancing Health Care
Brain tumor patients get tool to find clinical trials
The National Brain Tumor Society launched the Clinical Trial Finder, developed by brain tumor survivor Michael Wenger, to increase awareness about trials for brain tumor treatments and get more patients involved in them. The group also is working on programs to improve the research process, empower patients and give patients more input into development of clinical trials.
Patient Engagement HIT (3/22) 
LinkedIn Twitter Facebook Google+ Email
SNMMI Annual Meeting early-bird registration ends Thursday, April 13
Save up to $255 off on-site rates when you register by Thursday, April 13, for the SNMMI Annual Meeting. This year's meeting--taking place June 10-14 in Denver -- features more than 150 scientific and CE sessions, 1,000+ scientific posters, a world-class exhibit hall and more. Plus, get exclusive attendee only, pre-meeting rates on the Virtual Meeting and Virtual Poster Hall when you register. Make your plans today!
LinkedIn Twitter Facebook Google+ Email
Now available! ACNM/SNMMI Online MRI Case Review
ACNM and SNMMI have partnered to bring you the first-ever online MRI teaching modules as an introduction to interpreting MRI. The first set, Abdominal MRI Part I, is now available! Each set of 25 cases offers CME/SAM credit upon completion of the course. Register for Abdominal Part I.
LinkedIn Twitter Facebook Google+ Email
Learn more about SNMMI:
SNMMI | News & Publications | Meetings | Education
Membership | Support Education/Research in Your Field
We do not need magic to change the world. We carry all the power we need inside ourselves already: We have the power to imagine better.
J.K. Rowling,
LinkedIn Twitter Facebook Google+ Email
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Christopher Black
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information